Lumiere Raises Pre-A for Epigenetic Editing

Evidence Investor disclosure · Discovery September 12, 2026 · Importance 4/5 · Direction Positive Summary Lumiere Therapeutics, also known as Weiguang Gene in Chinese, completed a Pre-A financing of more than RMB100 million. Essential Capital and Huafang Capital co-led the round, joined by Yifeng Zhuohua,…